Dengue is a mosquito-borne viral disease that is transmitted by female mosquitoes mainly of the species Aedes aegypti and the causative agent of dengue is virus of the Flaviviridae family. Dengue can cause serious illness as well as death among the children. The world health organizations (WHO) estimated that 3.9 million people from 128 countries are at risk of infection from dengue virus.
Dengue is diagnosed by isolation of the virus, by molecular or by serology diagnostic methods. Even though several commercial kits for the diagnosis of dengue are available in the market, the concerns have emerged with respect to the performance of these kits.
Economically affordable commercial kits of adequate sensitivity and specificity that are able to diagnose dengue infection during the acute stage have not been developed. Medical governing bodies are working together to provide training on clinical management, diagnosis and vector control to their regions.
Hyper-endemicity of multiple dengue virus serotypes in many countries leads to increasing government initiatives to provide better healthcare facilities are contributing in market growth. According to WHO, incidence of dengue fever has increased as compared to previous few years and a large population is estimated to get exposed to dengue in future. However, lack of awareness in emerging nations and high diagnosis rate is estimated to hamper the dengue testing market growth.
The dengue testing market is segmented by product type, by end user and geography.
Dengue testing products include ELISA based test, RT-PCR based tests and dengue IgG/IgM rapid test. Dengue IgG/IgM rapid test is a quick solid phase immuno-chromatographic test for the qualitative detection of dengue antigen and differential detection of IgM and IgG antibodies to dengue virus in human serum/plasma.
Various end users in dengue testing industry are hospitals, public health laboratory and diagnostic centers. Also, it is used in research institutes and clinics. Diagnostic centers make use of dengue testing predominantly due to collaborations with hospitals and clinics.
Dengue testing market is analyzed across the various regions geographically including North America, Europe, Asia Pacific and rest of world. Severe dengue affects most Asian and Latin American countries and has become a leading cause of hospitalization and death among children and adults which has elicited the dengue testing market in these regions.
In 2018, the North America held the dominant position, due to increasing prevalence of dengue and research and developmental activities by key market players to develop better diagnostic tool. Asia pacific is expected to grow rapidly during projection period due to threat of a possible outbreak of dengue fever in the region.
Pivotal market players in the dengue testing market are Abbott Laboratories, InBios International, Inc., NovaTec Immundiagnostica GmbH, Euroimmun AG (Sub. PerkinElmer), Quest Diagnostics, Certest Biotec S.L., OriGene Technologies, Abnova Corporation, Arkray, Inc., Ceres Nanosciences, Roche Diagnostics International AG, Whidiag SAS and Thermo Fisher Scientific. Major players operating in this market are focusing on developing novel diagnostic tool for early detection of dengue. New technologies and ideal product launch are the key strategies adopted to enhance the market share. Recently, Roche announced the CE-IVD launch of the cobas MTB-RIF/INH test to detect resistance to antibiotics within tuberculosis DNA. This assay is part of the mycobacteria test menu that includes the cobas MTB and cobas MAI tests for use on the cobas 6800/8800 Systems.
The dengue testing market is segmented by product type, by end user and geography. Dengue testing products available are ELISA based test, RT-PCR based tests and dengue IgG/IgM rapid test. Different end users in dengue testing comprises of hospitals, public health laboratory and diagnostic centres.
Dengue testing market is studied across the various regions geographically including North America, Europe, Asia Pacific and rest of world. Dengue is found to be highly prevalent in Asian and Latin American countries.
The North America held the dominant position owing to research and developmental activities by key market players to develop better diagnostic tool in 2018. Asia pacific is expected to grow rapidly during projection period due to higher risk of a possible outbreak of dengue fever in the region. New technologies and ideal product launch are the key strategies adopted by the major market players to enhance the market share.
Why to buy this report: